Therapy Areas: Respiratory
Open Orphan signs GBP7.2m RSV human challenge study contract
14 June 2022 -

Contract research organisation Open Orphan plc (AIM:ORPH) (Euronext Growth:ORPH) announced on Tuesday a GBP7.2m deal for its subsidiary hVIVO.

This contract with an unnamed top 5 global pharmaceutical company is for testing of its orally administered antiviral product using hVIVO's respiratory syncytial virus (RSV) human challenge study model.

Commencing in June 2022, the Phase 2a double-blinded placebo-controlled human challenge study will evaluate the safety and efficacy profile of the antiviral against RSV.

The client's antiviral is currently in Phase III clinical trials for another infectious disease indication.




Related Headlines